Data is useful! But it seems like (I am not an economist) the incentive structures around these offices are failing. Maybe the benefits need to be more immediate / obvious / visceral.
First of all - very cool that they were able to image this and work out the mechanical mechanism in such detail.
Second - the rupture event looks so violent but iiuc it’s actually highly controlled:
- the rupture site is thinned early in the ovulation process
- the expansion step pulls in fluid to the ovary (builds internal pressure)
- the contraction phase restricts the cell volume (which also builds internal pressure)
- the oocyte is launched out of the cell at a relatively high speed
"the biggest problems in drug development are not really solved by having faster access to protein structures ... we have far bigger issues with target selection (does this idea of ours really do anything against the disease, in the end?) and with unexpected toxicity (what else does our candidate do in real animals and real humans?) Those last two are where that 90% clinical failure rate comes from."
Who is your ideal user? Do you think this person frequents ProductHunt? That's your answer.
My experience is that the main users of PH are those launching a product.
I'll also add: after my PH launch, I experienced a lot of email spam from "growth hacker" types. I suspect they scrape PH. I tried to take down our post (because the spam was overwhelming), but PH refused.
Where there isn't an available crystal structure, Alphafold can be used to create initial structures for simulation via folding@home, replacing older homology modeling techniques.
Super cool, congrats to the team! I can't count how many times I've had to open the merging section of the pandas docs. Great library but I find a lot of it unintuitive and hard to commit to memory.